UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **June 21, 2023**

PTC THERAPEUTICS, INC.

(Exact Name of Company as Specified in Charter)

Delaware	**001-35969**	**04-3416587**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

100 Corporate Court **South Plainfield, NJ**	**07080**
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: **(908) 222-7000**

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, $0.001 par value per share	PTCT	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

PTC Therapeutics, Inc. (the "Company") will host a conference call on June 21, 2023 at 8:00 a.m. eastern time. During this conference call, the Company expects to discuss interim data from the initial 12-week portion of its Phase 2 study of PTC518 for the treatment of Huntington's disease. Directions on how to access the conference call are included in the press release furnished as Exhibit 99.1 hereto. A copy of the slide deck that will be presented during the conference call is furnished as Exhibit 99.2 hereto.

The information in this Item 7.01 of this Current Report on Form 8-K ("Report"), including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release, dated June 21, 2023 issued by PTC Therapeutics, Inc.
99.2	Corporate Presentation – PIVOT-HD Interim Data Update
104	The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

PTC Therapeutics, Inc.

Date: June 21, 2023

By: /s/ Mark E. Boulding
Name: Mark E. Boulding
Title: Executive Vice President and Chief Legal Officer

PTC Therapeutics Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington's Disease Patients

- Dose-dependent lowering of blood Huntingtin (HTT) protein levels at 12 weeks -
- Favorable tolerability profile with no treatment-related serious adverse events or NfL spikes -

- Conference call and webcast to be held June 21st at 8:00 am EDT -

SOUTH PLAINFIELD, N.J., June 21, 2023 -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today shared interim data from the 12-week portion of the PIVOT-HD Phase 2 study of PTC518 in Huntington's disease (HD) patients. The study demonstrated dose-dependent lowering of Huntingtin (HTT) protein levels in peripheral blood cells, reaching a mean 30% reduction in mutant HTT levels at the 10mg dose level. In addition, PTC518 exposure in the cerebrospinal fluid (CSF) was consistent with or higher than plasma unbound drug levels.

PTC518 treatment was also demonstrated to be well tolerated, with no treatment-related serious adverse events, no reports of peripheral neuropathy or dose-limiting toxicities. Furthermore, there were no CSF neurofilament light chain protein (NfL) treatment-related spikes, with an overall trend towards lowering of CSF NfL levels following 12 weeks of PTC518 treatment.

"We are very pleased with the encouraging data from the PIVOT-HD interim analysis demonstrating dose-dependent HTT lowering, desired CSF exposure and a favorable tolerability profile without evidence of treatment-related serious adverse events or CSF NfL spikes," said Dr. Matthew Klein, Chief Executive Officer, PTC Therapeutics, Inc.

PIVOT-HD is a global, placebo-controlled study and consists of two parts: an initial 12-week placebo-controlled phase focused on PTC518 pharmacology and pharmacodynamic effect, followed by a 9-month placebo-controlled portion. The study will initially include two dose levels, 5 milligrams and 10 milligrams, with the ability to include a third dose level of up to 20 milligrams.

Today's Conference Call and Webcast
PTC will hold a conference call at 8:00 am EDT today to discuss this news. To access the call by phone, please click here to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call. The webcast conference call can be accessed on the Investor section of the PTC website at https://ir.ptcbio.com/events-presentations. A replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for 30 days following the call.

About PTC518
PTC is developing a potential treatment for Huntington's disease based on our splicing platform technology. PTC518, a small molecule that can be taken orally, reduces the production of the mutated Huntingtin protein that leads to injury and death of the neuron, which results in disease progression. The orally bioavailable small molecule penetrates the blood brain barrier, is selective, titratable, and not effluxed – which are key differentiation properties.

About Huntington's Disease
Huntington's disease (HD) is a rare, hereditary, genetic disorder of the central nervous system.[1] It is caused by a defective gene. This gene produces a protein, called Huntingtin, which is involved in the functioning of the nerve cells in the brain (neurons). When the gene is defective, it produces an abnormal (or mutated) Huntingtin protein that is toxic and causes neuron damage and neuron death.[2] HD usually presents in people who are in their 30s or 40s. Symptoms can present earlier in life, and this is called the Juvenile HD.[2,3] There are also cases of infantile HD, when symptoms develop in children who are younger than 10 years old.[2] While symptoms vary from person to person, the disease primarily affects the brain and results in abnormal movements, difficulties with speech, swallowing and walking, as well as a number of other symptoms including behavioral, cognitive and motor symptoms. [4,5] While there are

therapies approved for specific disease symptoms, currently, there is no cure for HD and there are no approved drugs that delay the onset or slow disease progression.

About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. PTC's mission is to provide access to best-in-class treatments for patients who have little to no treatment options. PTC's strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. PTC believes this allows it to maximize value for all its stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, Instagram, LinkedIn and Twitter at @PTCBio.

For More Information:
Investors:
Kylie O'Keefe
+1 (908) 300-0691
kokeefe@ptcbio.com

Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com

Forward-Looking Statement
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historic fact, are forward-looking statements, including statements with respect to the future expectations, plans and prospects for PTC, PTC's strategy, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses and other matters, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.

PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward -looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates; PTC's scientific approach and general development progress; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of PTC's most recent Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful.

The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.

References:

1. World Health Organization, 2020. 8A01.10 Huntington disease. Available at: https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/2132180242 Accessed October 2021.
2. Gatto EM, González Rojas N, Persi G, et al. Clin Parkinsonism Rel Disord 2020;3:100056.
3. Tabrizi SJ, Flower MD, Ross CA, et al. Nat Rev Neurol 2020;16(10):529–546.
4. Roos RAC. Orphanet J Rare Dis 2010;5:40.
5. Kirkwood SC, Su JL, Conneally P, et al. Arch Neurol 2001;58(2):273–278.

PIVOT-HD Interim Data Update

Matthew Klein, M.D.
CEO

June 2023

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historic fact, are forward-looking statements, including statements with respect to the future expectations, plans and prospects f PTC, PTC's strategy, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses and other matters, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," similar expressions.

PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a vari of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; significant business effects, including the effects of industry, market, economic, politic regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates; PTC's scientific approach and general development progress; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the fut for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of PTC's most recent Annu Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all suc factors.

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are r guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful.

The forward-looking statements contained herein represent PTC's views only as of the date of this presentation and PTC does not undertake or plan to update or revis any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring a the date of this presentation except as required by law.

PTC518 Program Leveraged Learnings from Successful Development of Evrysdi

PTC518 developed from PTC's validated splicing platform

Databases of Splicing Targets



Novel Chemical Library



HTSpliceseq

Expert Team

Key learnings from successful development of Evrysdi

- Importance of molecule selectivity and specificit
- CNS bioavailability with broad brain biodistribution
- Leverage systemic exposure to confirm target engagement and splicing activity and inform dose selection

Evrysdi risdiplam

Key Objectives for 12-Week Interim Data Readout

- Determine HTT protein lowering after 12 weeks of treatment with PTC518 at 5mg and 10mg
- Define CSF/plasma drug exposure in Huntington's disease patients
- Confirm the relationship of HTT mRNA to protein lowering at steady state
- Evaluate PTC518 safety and tolerability

12-Week Interim Data Met Key Objectives

- **PTC518 treatment resulted in dose-dependent lowering** of HTT mRNA and protein levels in blood cells
- **PTC518 demonstrated desired CSF exposure** with higher concentrations of free drug in the CSF than plasma
- **PTC518 was well tolerated** with no treatment-related serious adverse events and no reports of peripheral neuropathy
- **CSF NfL levels remained stable** after 12 weeks of treatment with no treatment-related spikes

PIVOT-HD Study Design



Primary Endpoints

- Safety and tolerability of PTC518
- Percent reduction in HTT mRNA and protein in blood

Secondary Endpoints

- Percent reduction in mHTT protein in CSF
- Changes in neurofilament light chain (NfL) in plasma and CSF
- Change in brain volume on volumetric MRI imaging

PIVOT-HD Trial Populations

Inclusion Criteria
Stage 2

- Ambulatory Huntington's patients age 25 and older
- CAG repeats 40-50 inclusive
- Motor and Cognitive Function:
  - UHDRS-IS score of **100**
  - UHDRS TFC score of **13**
- PIN_{HD} score of **0.18 - 4.93**
  - Multivariate calculation including SDMT, TMS, age, CAG

Inclusion Criteria
Early Stage 3

- Ambulatory Huntington's patients age 25 and older
- CAG repeats 40-50 inclusive
- Motor and Cognitive Function:
  - UHDRS-IS score of **less than 100 and/or**
  - UHDRS TFC score of **11 or 12**

PIVOT-HD Interim Analysis Patient Characteristics

Category	PTC518 5mg (N=13)	PTC518 10mg (N=11)	Placebo (N=9)	Overall (N=33)
Age (years) mean	46.2	47.4	46.9	46.8
Gender, n (%)				
Male	5 (38.5%)	6 (54.5%)	6 (66.7%)	17 (51.5%)
Female	8 (61.5%)	5 (45.5%)	3 (33.3%)	16 (48.5%)
CAG length				
Mean (SD)	44.08 (1.9)	43.73 (2.4)	44.11 (2.0)	43.97 (2.1)
Min – Max	42 - 49	42 - 50	42 - 47	42 – 50
TFC (Total Functional Capacity) Score				
Mean	13	13	13	13

PTC518 Treatment Resulted in Dose-Dependent Blood HTT Protein Lowering at Week 12



Note: Error bars represent the standard error of the mean.

Mean % change from baseline mRNA (Week 12)	
-27%	-29%

Dose-dependent lowering of HTT protein

mRNA and protei lowering **~1:1**

PTC518 CSF Drug Levels Confirm Targeted CNS Exposure at Week 12

Treatment Group	Mean CSF Concentration (ng/mL)	Mean Free Plasma Concentration (ng/mL)
5mg	0.923	0.917
10mg	2.037	1.402

Ratio of CSF to Free Plasma Concentration

5mg **1.1 to 1**

10mg **1.5 to 1**

PTC518 Treatment Demonstrated to Be Well Tolerated

PTC518 was well tolerated, with no treatment-related serious adverse events and no adverse events leading to discontinuation

Similar adverse event profile across treatment groups, including placebo group

Most common adverse events were upper respiratory tract infection and headache

PTC518 Treatment Demonstrated to Be Well Tolerated

Category	PTC518 5mg (N = 13)	PTC518 10mg (N=11)	Placebo (N=9)	Overall (N=33)
Subjects with at least one TEAE	9 (69.2)	7 (63.6)	6 (66.7)	22 (66.7)
Subjects with at least one serious TEAE	0	0	0	0
Subjects with at least one TEAEs leading to study treatment discontinuation	0	0	0	0
Subjects with at least one TEAE leading to death	0	0	0	0
Subjects with at least one treatment related AE#	3 (23.1)	4 (36.4)	1 (11.1)	8 (24.2)
Subjects with at least one TEAEs by maximum severity N (%)	9 (69.2)	7 (63.6)	6 (66.7)	22 (66.7)
Grade 1	4	2	5	11
Grade 2	4	5	1	10
Grade 3	1*	0	0	1
Grade 4/5	0	0	0	0

* Unrelated to drug
# Judged by the investigator to be probably or possibly related to treatment

CSF NfL Levels Trended Lower in Subjects Treated with PTC518

Individual Subject CSF NfL Trajectories



Note: One patient excluded due to non-treatment related viral syndrome.

Mean Change in CSF NfL Levels from Baseline to Week



Note: Error bars represent the standard error of the mean.

Summary and Next Steps

Dose-dependent lowering of HTT protein levels, safety, and CNS biodistribution objectives achieved

Continue enrollment in Stage 2 and early Stage 3 patient cohorts

Share safety data with FDA to support US enrollment in PIVOT-HD